Biotech News

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Rallybio (RLYB)Rallybio2026-06-25 13:46 ESTClinical readout

– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion Refractoriness Currently Planned for 2H 2026 with Potential for Topline Data in 2027 – NEW HAVEN,

Open original release

Related news

RLYBRallybio2026-06-25 13:46 EST

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

RLYBRallybio2026-06-25 13:46 EST

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

RLYBRallybio2026-06-25 13:46 EST

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

RLYBRallybio2026-06-25 13:46 EST

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

RLYBRallybio2026-06-25 13:46 EST

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

RLYBRallybio2026-06-25 13:46 EST

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

RLYBRallybio2026-06-25 13:46 EST

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

RLYBRallybio2026-06-25 13:46 EST

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

RLYBRallybio2026-06-25 13:46 EST

Rallybio Announces Reverse Stock Split of Common Stock

RLYBRallybio2026-06-25 13:46 EST

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

View all latest news

Rallybio

Rallybio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

RLYBZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

RLYBZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

RLYBBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

RLYBGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

RLYBMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 15.89 USD
Market cap: 91.23M USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States